Hiroyuki Fukase

Tokyo, JP 
Tokyo, JP 

Overview

Hiroyuki Fukase practices practicing medicine in Tokyo, Japan.

His clinical expertise encompasses Peptic Ulcer, Maturity Onset Diabetes of the Young, and Pericarditis.

He is actively involved in clinical research, co-authoring 17 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Tokyo, Japan
Other Locations
Shinjuku, 1620053, Japan
Kagoshima, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: July 16, 2026
Intervention Type: Drug
Study Drug: LY3502970
Study Phase: Phase 1
A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have the PNPLA3 I148M Genotype
A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have the PNPLA3 I148M Genotype
Enrollment Status: Completed
Publish Date: June 24, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants
Enrollment Status: Completed
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drug: LY3372993
Study Phase: Phase 1
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: LY3437943
Study Phase: Phase 1
A Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3537031 in Healthy Participants
A Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3537031 in Healthy Participants
Enrollment Status: Completed
Publish Date: June 21, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

17 Total Publications

Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan.
Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan.
Journal: Vaccine
Published: April 27, 2026

Frequently Asked Questions about Hiroyuki Fukase

Is Hiroyuki Fukase a top-rated expert for Peptic Ulcer?

MediFind is an objective health platform that identifies experts based on real-world data. Hiroyuki Fukase is classified as an Experienced expert for Peptic Ulcer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hiroyuki Fukase participate in research or clinical trials?

Yes. Hiroyuki Fukase has published 17 articles and abstracts on conditions like Peptic Ulcer. You can view a list of Hiroyuki Fukase's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fukase's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile